Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system

Anokhi Jambusaria-Pahlajani, Peter A. Kanetsky, Pritesh S. Karia, Wei Ting Hwang, Joel M. Gelfand, Faith M. Whalen, Rosalie Elenitsas, Xiaowei Xu, Chrysalyne D. Schmults

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Importance: This study proposes an alternative tumor staging system for cutaneous squamous cell carcinoma (CSCC) that more precisely defines the small subset of tumors with a high risk of metastasis and death. Objective: To identify risk factors for poor outcomes in CSCC and evaluate the 2010 American Joint Committee on Cancer (AJCC) tumor (T) staging system's ability to stratify occurrence of these outcomes. Design: Retrospective cohort study. Setting: A single academic hospital. Participants: Study participants were identified via a pathology and dermatopathology database search for patients diagnosed as having high-risk CSCC. Results: Two hundred fifty-six primary high-risk CSCCs were included. Outcomes for AJCC tumor stages T2 to T4 were statistically indistinguishable because only 4 cases (<2% of the cohort) were AJCC stages T3 or T4, which require bone invasion. Subsequently, the bulk of poor outcomes (83% of nodal metastases, 92% of deaths from CSCC) occurred in AJCC stage T2 cases. An alternative tumor staging system was developed with the aim of better stratifying this stage T2 group. Four risk factors were found to be statistically independent prognostic factors for at least 2 outcomes of interest in multivariate modeling. These factors (poor differentiation, perineural invasion, tumor diameter ≥2 cm, invasion beyond subcutaneous fat) were incorporated in the alternative staging with 0 factors indicating T1, 1 factor indicating T2a; 2 to 3 factors, T2b; and 4 factors or bone invasion, T3. Stages T2a and T2b significantly differed in incidences of all 4 end points. Stage T2b tumors comprised only 19% of the cohort but accounted for 72% of nodal metastases and 83% of deaths from CSCC. Conclusions and Relevance: The proposed alternative tumor staging system offers improved prognostic discrimination via stratification of stage T2 tumors. Validation in other cohorts is needed. Meanwhile, stage T2b tumors are responsible for most poor outcomes and may be a focus of high-risk CSCC study.

Original languageEnglish (US)
Pages (from-to)402-410
Number of pages9
JournalJAMA Dermatology
Volume149
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Neoplasm Staging
Squamous Cell Carcinoma
Skin
Neoplasms
Neoplasm Metastasis
Bone and Bones
Subcutaneous Fat
Cohort Studies
Retrospective Studies
Databases
Pathology

ASJC Scopus subject areas

  • Dermatology

Cite this

Jambusaria-Pahlajani, A., Kanetsky, P. A., Karia, P. S., Hwang, W. T., Gelfand, J. M., Whalen, F. M., ... Schmults, C. D. (2013). Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatology, 149(4), 402-410. https://doi.org/10.1001/jamadermatol.2013.2456

Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. / Jambusaria-Pahlajani, Anokhi; Kanetsky, Peter A.; Karia, Pritesh S.; Hwang, Wei Ting; Gelfand, Joel M.; Whalen, Faith M.; Elenitsas, Rosalie; Xu, Xiaowei; Schmults, Chrysalyne D.

In: JAMA Dermatology, Vol. 149, No. 4, 04.2013, p. 402-410.

Research output: Contribution to journalArticle

Jambusaria-Pahlajani, A, Kanetsky, PA, Karia, PS, Hwang, WT, Gelfand, JM, Whalen, FM, Elenitsas, R, Xu, X & Schmults, CD 2013, 'Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system', JAMA Dermatology, vol. 149, no. 4, pp. 402-410. https://doi.org/10.1001/jamadermatol.2013.2456
Jambusaria-Pahlajani, Anokhi ; Kanetsky, Peter A. ; Karia, Pritesh S. ; Hwang, Wei Ting ; Gelfand, Joel M. ; Whalen, Faith M. ; Elenitsas, Rosalie ; Xu, Xiaowei ; Schmults, Chrysalyne D. / Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. In: JAMA Dermatology. 2013 ; Vol. 149, No. 4. pp. 402-410.
@article{e8f6db5170cd479ea7288e585af1f139,
title = "Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system",
abstract = "Importance: This study proposes an alternative tumor staging system for cutaneous squamous cell carcinoma (CSCC) that more precisely defines the small subset of tumors with a high risk of metastasis and death. Objective: To identify risk factors for poor outcomes in CSCC and evaluate the 2010 American Joint Committee on Cancer (AJCC) tumor (T) staging system's ability to stratify occurrence of these outcomes. Design: Retrospective cohort study. Setting: A single academic hospital. Participants: Study participants were identified via a pathology and dermatopathology database search for patients diagnosed as having high-risk CSCC. Results: Two hundred fifty-six primary high-risk CSCCs were included. Outcomes for AJCC tumor stages T2 to T4 were statistically indistinguishable because only 4 cases (<2{\%} of the cohort) were AJCC stages T3 or T4, which require bone invasion. Subsequently, the bulk of poor outcomes (83{\%} of nodal metastases, 92{\%} of deaths from CSCC) occurred in AJCC stage T2 cases. An alternative tumor staging system was developed with the aim of better stratifying this stage T2 group. Four risk factors were found to be statistically independent prognostic factors for at least 2 outcomes of interest in multivariate modeling. These factors (poor differentiation, perineural invasion, tumor diameter ≥2 cm, invasion beyond subcutaneous fat) were incorporated in the alternative staging with 0 factors indicating T1, 1 factor indicating T2a; 2 to 3 factors, T2b; and 4 factors or bone invasion, T3. Stages T2a and T2b significantly differed in incidences of all 4 end points. Stage T2b tumors comprised only 19{\%} of the cohort but accounted for 72{\%} of nodal metastases and 83{\%} of deaths from CSCC. Conclusions and Relevance: The proposed alternative tumor staging system offers improved prognostic discrimination via stratification of stage T2 tumors. Validation in other cohorts is needed. Meanwhile, stage T2b tumors are responsible for most poor outcomes and may be a focus of high-risk CSCC study.",
author = "Anokhi Jambusaria-Pahlajani and Kanetsky, {Peter A.} and Karia, {Pritesh S.} and Hwang, {Wei Ting} and Gelfand, {Joel M.} and Whalen, {Faith M.} and Rosalie Elenitsas and Xiaowei Xu and Schmults, {Chrysalyne D.}",
year = "2013",
month = "4",
doi = "10.1001/jamadermatol.2013.2456",
language = "English (US)",
volume = "149",
pages = "402--410",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system

AU - Jambusaria-Pahlajani, Anokhi

AU - Kanetsky, Peter A.

AU - Karia, Pritesh S.

AU - Hwang, Wei Ting

AU - Gelfand, Joel M.

AU - Whalen, Faith M.

AU - Elenitsas, Rosalie

AU - Xu, Xiaowei

AU - Schmults, Chrysalyne D.

PY - 2013/4

Y1 - 2013/4

N2 - Importance: This study proposes an alternative tumor staging system for cutaneous squamous cell carcinoma (CSCC) that more precisely defines the small subset of tumors with a high risk of metastasis and death. Objective: To identify risk factors for poor outcomes in CSCC and evaluate the 2010 American Joint Committee on Cancer (AJCC) tumor (T) staging system's ability to stratify occurrence of these outcomes. Design: Retrospective cohort study. Setting: A single academic hospital. Participants: Study participants were identified via a pathology and dermatopathology database search for patients diagnosed as having high-risk CSCC. Results: Two hundred fifty-six primary high-risk CSCCs were included. Outcomes for AJCC tumor stages T2 to T4 were statistically indistinguishable because only 4 cases (<2% of the cohort) were AJCC stages T3 or T4, which require bone invasion. Subsequently, the bulk of poor outcomes (83% of nodal metastases, 92% of deaths from CSCC) occurred in AJCC stage T2 cases. An alternative tumor staging system was developed with the aim of better stratifying this stage T2 group. Four risk factors were found to be statistically independent prognostic factors for at least 2 outcomes of interest in multivariate modeling. These factors (poor differentiation, perineural invasion, tumor diameter ≥2 cm, invasion beyond subcutaneous fat) were incorporated in the alternative staging with 0 factors indicating T1, 1 factor indicating T2a; 2 to 3 factors, T2b; and 4 factors or bone invasion, T3. Stages T2a and T2b significantly differed in incidences of all 4 end points. Stage T2b tumors comprised only 19% of the cohort but accounted for 72% of nodal metastases and 83% of deaths from CSCC. Conclusions and Relevance: The proposed alternative tumor staging system offers improved prognostic discrimination via stratification of stage T2 tumors. Validation in other cohorts is needed. Meanwhile, stage T2b tumors are responsible for most poor outcomes and may be a focus of high-risk CSCC study.

AB - Importance: This study proposes an alternative tumor staging system for cutaneous squamous cell carcinoma (CSCC) that more precisely defines the small subset of tumors with a high risk of metastasis and death. Objective: To identify risk factors for poor outcomes in CSCC and evaluate the 2010 American Joint Committee on Cancer (AJCC) tumor (T) staging system's ability to stratify occurrence of these outcomes. Design: Retrospective cohort study. Setting: A single academic hospital. Participants: Study participants were identified via a pathology and dermatopathology database search for patients diagnosed as having high-risk CSCC. Results: Two hundred fifty-six primary high-risk CSCCs were included. Outcomes for AJCC tumor stages T2 to T4 were statistically indistinguishable because only 4 cases (<2% of the cohort) were AJCC stages T3 or T4, which require bone invasion. Subsequently, the bulk of poor outcomes (83% of nodal metastases, 92% of deaths from CSCC) occurred in AJCC stage T2 cases. An alternative tumor staging system was developed with the aim of better stratifying this stage T2 group. Four risk factors were found to be statistically independent prognostic factors for at least 2 outcomes of interest in multivariate modeling. These factors (poor differentiation, perineural invasion, tumor diameter ≥2 cm, invasion beyond subcutaneous fat) were incorporated in the alternative staging with 0 factors indicating T1, 1 factor indicating T2a; 2 to 3 factors, T2b; and 4 factors or bone invasion, T3. Stages T2a and T2b significantly differed in incidences of all 4 end points. Stage T2b tumors comprised only 19% of the cohort but accounted for 72% of nodal metastases and 83% of deaths from CSCC. Conclusions and Relevance: The proposed alternative tumor staging system offers improved prognostic discrimination via stratification of stage T2 tumors. Validation in other cohorts is needed. Meanwhile, stage T2b tumors are responsible for most poor outcomes and may be a focus of high-risk CSCC study.

UR - http://www.scopus.com/inward/record.url?scp=84876821836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876821836&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2013.2456

DO - 10.1001/jamadermatol.2013.2456

M3 - Article

VL - 149

SP - 402

EP - 410

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 4

ER -